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Background/aim: Aluminum phosphide (AlP) is commonly used as a fumigant in developing countries. Induction of oxidative stress is
one of the most important mechanisms of its toxicity. In this regard, and considering that there is no specific antidote for its treatment,
the aim of this study was to evaluate the effect of vitamin E in the treatment of acute AlP poisoning.
Materials and methods: This was a clinical trial on acute AlP poisoned patients. All patients received supportive treatment. In addition,
the treatment group received vitamin E (400 mg/BD/IM). Level of malondialdehyde (MDA) and total antioxidant capacity of plasma
were measured.
Results: There was no significant difference between the treatment and control groups with regard to demographic, clinical, or
paraclinical data or Simplified Acute Physiology Score II (SAPSII) on admission. Systolic blood pressure significantly increased during
the first 24 h in the treatment group (P < 0.05). The plasma MDA level significantly decreased in the treatment group (P < 0.05). Vitamin
E administration decreased the necessity (30% vs. 62%, P < 0.05) and duration of intubation and mechanical ventilation (P < 0.05). It
significantly reduced the mortality rate in the treatment group compared to the control group (15% vs. 50%, respectively, P < 0.05).
Conclusion: Vitamin E along with supportive treatment could have a therapeutic effect in acute AlP poisoning.
Key words: Aluminum phosphide, oxidative stress, poisoning, vitamin E

1. Introduction
Aluminum phosphide (AlP) is used widely throughout
the world as a pesticide and fumigant because of
its efficacy and low cost (1). AlP is one of the most
frequently reported causes of acute chemical poisoning
in Asia (2–4). In Iran, it is available in 3-g tablets
containing 1 g of AlP and known as “rice tablet”; it
causes acute poisoning with a high mortality rate (5–7).
AlP toxicity is due to liberating phosphine (PH3) gas
after its reaction with moisture, water, or hydrochloric
acid in the stomach (8,9). The major of mortality occurs
during the first 12–24 h after exposure and is mostly
due to cardiovascular and respiratory involvement
(8,9).
The exact mechanism of phosphine toxicity is not
clear and some mechanisms are reported (8,9). Previous
studies suggested that the induction of oxidative stress
has the main role in AlP toxicity (10,11), which is
emphasized by recent studies (12–15).
* Correspondence: shahin1380@yahoo.com

As there is no specific antidote for acute AlP poisoning,
its treatment is mainly supportive and symptomatic
(1,8,9). By considering the induction of oxidative stress as
the main mechanism of AlP toxicity and with regard to
the role of vitamin E in the enzymatic antioxidants defense
and function as a free radical scavenger (16–18), its use
may have a therapeutic effect in the treatment of AlPpoisoned patients.
The aim of the present study was to investigate the
therapeutic effects of vitamin E in acute human AlP
poisoning.
2. Materials and methods
2.1. Patients
This was a prospective, randomized, control open label
trial on acute AlP intoxicated patients that were treated in
the intensive care unit (ICU) over a 1-year period.
Acute AlP-intoxicated patients above the age of 12
years who were admitted during the first 6 h after exposure
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with no advanced medical management for AlP poisoning
in any medical center before admission were included in
this study. The exclusion criteria were history of diabetes
mellitus, cardiovascular, respiratory, renal, and hepatic
failure, substance abuse, and co-ingestion.
The diagnosis was confirmed based on history of
exposure, clinical manifestations, laboratory findings,
and other circumstantial evidence such as availability of a
poison bottle or a label. In fatal cases, toxicological analysis
and a histopathological examination were performed.
A positive silver nitrate test for PH3 gas on stomach
contents and tissues along with the liver postmortem
histopathological findings confirmed the AlP poisoning.
According to the mentioned criteria, 36 patients were
included in the study consecutively. Each patient with an
even file number was included in the vitamin E treatment
group (n = 20) and the patients with odd file numbers were
included in the control group (n = 16).
2.2. Study design and treatments
All the patients received gastric decontamination with
sodium bicarbonate (44 mEq), permanganate potassium
(1:10,000), and activated charcoal (1 g/kg) in the first
6 h after exposure. All the patients were admitted to the
ICU, as they needed intubation, mechanical ventilation,
and intensive monitoring. They were treated with the
same protocol (magnesium sulfate 4–6 g by IV infusion
daily, calcium gluconate 4 g by IV infusion daily,
adequate hydration, and norepinephrine 10 µg/min as
vasopressor) under the supervision of the same physicians
and nurses. The described treatments were based on the
clinical toxicology department protocols. In the vitamin
E treatment group, vitamin E (as DL-alpha tocopheryl
acetate, 100 IU/mL, OSVAH Pharmaceutical Co. Tehran,
Iran; 400 mg/IM, every 12 h) was administered up to 72 h.
We followed the patients up to discharge from the hospital
or death.
The protocol of the study was approved by the ethical
committee of Shahid Beheshti University of Medical
Sciences, Tehran, Iran.
2.3. Sampling and bioanalysis
Blood sampling was performed at the admission on
hospital and repeated each 24 h up to 72 h of hospitalization
in the ICU. Venous blood samples (5 mL) were collected in
different heparinized tubes and then plasma samples were
separated via centrifugation at 3500 rpm for 10 min and
frozen at –80 °C. On average, the time interval between
sampling and analysis was 1 week. Lipid peroxidation in the
plasma in two groups was evaluated by the thiobarbituric
acid reactive substances (TBARS) method (19). First
250 µL of 20% trichloroacetic acid (TCA) in 10 mL of
sodium sulfate (2 M) was added to 0.5 mL of plasma. After
precipitation of the protein with TCA, washing with 300
µL of sulfuric acid (0.05 M) was performed. Then 300 µL of
thiobarbituric acid (TBA) (0.67% w/v) solution was added
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to the mixture. The mixture was incubated in a boiling
water bath for 30 min. After cooling, the samples were
extracted with n-butanol and centrifuged at 3500 rpm.
The absorbance was read at 530 nm by ELISA microplate
reader (Synergy, BioTech Instruments Inc, Germany).
1,1,3,3-Tetramethoxy propane was used for drawing the
calibration curve. Malondialdehyde (MDA) was expressed
as micromoles of MDA per liter of plasma.
The total antioxidant capacity (TAC) of plasma was
evaluated using the ferric reducing ability of plasma
(FRAP) assay (20). Ferric tripyridyltirazine (Fe3+-TPTZ)
complex is reduced to the blue color marker ferrous (Fe2+)
form at acidic pH. To 50 µL of plasma was added 1500
µL of freshly prepared FRAP reagent [25 mL of acetate
buffer (pH = 3.6, 300 mmol/L), 2.5 mL of FeCl3, 6H2O
(20 mmol/L), 2.5 mL of TPTZ (10 mmol/L TPTZ in 40
mmol/L HCl)]. After 15 min incubation at 37 °C in a water
bath, absorbance was determined by ELISA microplate
reader (Synergy, BioTech Instruments Inc, Germany) at
593 nm. Then samples were placed at 37 °C in the water
bath and absorption was measured after 4 min. FRAP
values were measured by calculation of the absorbance
change in plasma sample compared with that of trolox
standard (20).
2.4. Data collection and statistical analysis
We collected patients’ information regarding sex, age, cause
of poisoning, number of ingested AlP tablets, time interval
between exposure and beginning of treatment, route of
exposure, clinical and laboratory findings at admission
and during the first 24 h of hospitalization, duration of
hospitalization, and outcome and prepared qualifying case
records. All data were kept confidential during the study.
The Glasgow Coma Scale (GCS) and Simplified Acute
Physiology Score II (SAPSII) were calculated at admission
(21,22). All data were analyzed with SPSS version 12. Data
were expressed as mean ± SD for quantitative variables
and as frequency and percentage for qualitative variables.
The chi-square test was used for statistical comparison
of qualitative variables. The normal distribution of
quantitative variables was tested by Kolmogorov–
Smirnov test. The Mann–Whitney U-test was used for
nonparametric variables and the independent Student’s
t-test was used for parametric variables. P values of 0.05 or
less were considered statistically significant.
3. Results
In the present study, 36 patients (13 men, 23 women) with
acute AlP poisoning were included, of whom 20 (5 men,
15 women) were in the treatment group and 16 (8 men, 8
women) were controls. The route of exposure was deliberate
ingestion in all patients. The main clinical manifestation
was vomiting, observed in the most of the patients in the
treatment and control groups (90% vs. 87.5%, respectively).
Table 1 summarizes the demographic, clinical, and
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Table 1. Distribution of the AlP intoxicated patients according to demographic, clinical, and paraclinical characteristics at admission.
All patients (n = 36)
(%) Mean ± SD (range)

Treatment group (n = 20)
(%) Mean ± SD (range)

Control group (n = 16)
(%) Mean ± SD (range)

P-value

Male

13 (26)

5 (25)

8 (50)

0.17▲

Female

23 (64)

15 (75)

8 (50)

Age (years)

25.56 ± 8.37 (14–50)

24.95 ± 8.11 (15–44)

26.31 ± 8.90 (14–50)

0.46♦

Number of AlP tablets

1.40 ± 0.86 (0.25–4)

1.28 ± 0.75 (0.25–3)

1.57 ± 1 (0.5–4)

0.48♦

TBOPAH$ (min)

87.50 ± 64.36 (15–300)

98.25 ± 76.66 (15–300)

74.06 ± 43.29 (15–180)

0.52♦

consciousness

20 (56)

11 (55)

9 (56)

1▲

unconsciousness

16 (44)

9 (45)

7 (44)

Systolic blood pressure (≤120 mmHg)

89.46 ± 15.76 (56–130)

89.16 ± 17.95 (56–130)

89.81 ± 13.29 (60–110)

0.90●

Diastolic blood pressure (≤80 mmHg)

57.79 ± 11.06 (37–80)

55.76 ± 11.03 (37–80)

60.67 ± 10.91 (40–70)

0.25●

Pulse rate (60–100 beats/min)

92.46 ± 15.94 (65–130)

90.50 ± 16.68 (65–130)

95.07 ± 15.04 (70–122)

0.41●

Respiratory rate (16–24 breaths/min)

19.25 ± 4.08 (12–30)

19.95 ± 4.16 (14–30)

18.38 ± 3.93 (12–26)

0.32♦

Normal

20 (56)

13 (65)

7 (44)

0.31▲

Abnormal

Parameter (normal range, unit)
Sex

Level of consciousness

Electrocardiogram

16 (44)

7 (35)

9 (56)

pH (7.35–7.45)

7.39 ± 0.08 (7.22–7.49)

7.40 ± 0.07 (7.24 ± 7.48)

7.38 ± 0.09 (7.22–7.49)

0.50●

PCO2 (35–45 mmHg)

30.03 ± 7.35 (16.90–43.10)

31.81 ± 7.06 (16.90–42.20)

27.81 ± 7.30 (18.10–43.10)

0.11●

Serum HCO3 (22–26 mEq/L)

18.64 ± 5.15 (9–29.1)

20.06 ± 5.47 (9.90–29.10)

16.88 ± 4.24 (9–24.5)

0.06●

Blood glucose (70–110 mg/dL)

148.75 ± 55.73 (74–282)

125.25 ± 48 (74–242)

178.13 ± 51.70 (101–282)

0.003**●

Blood urea nitrogen (7–18 mg/dL)

27.25 ± 11.61 (12–60)

29.45 ± 12.85 (12–60)

24.50 ± 9.51 (12–40)

0.20●

Creatinine (0.6–1.2 mg/dL)

0.94 ± 0.21 (0.60–1.40)

0.91 ± 0.21 (0.70–1.40)

1 ± 0.21 (0.60–1.30)

0.20♦

Sodium (135–145 mEq/L)

143.94 ± 5.07 (135–156)

143.40 ± 4.89 (137–155)

144.67 ± 5.38 (135–156)

0.48●

Potassium (3.5–5 mEq/L)

3.94 ± 0.46 (3–5.10)

3.86 ± 0.41 (3–4.60)

4.05 ± 0.53 (3.20–5.10)

0.52♦

Calcium (8.4–10.2 mg/dL)

8.82 ± 0.79 (7.50–10.50)

8.74 ± 0.86 (7.50–10.40)

8.91 ± 0.72 (8–10.50)

0.55●

Magnesium (1.9–2.5 mg/dL)

2.18 ± 0.58 (1.40–4)

2.08 ± 0.58 (1.40–4)

2.41 ± 0.56 (1.90–3.50)

0.07♦

White blood cell count (7–10 × 1000/µL)

15.55 ± 22.61 (3.20–141)

17.47 ± 29.42 (3.20–141)

12.81 ± 4.35 (5.80–20.60)

0.44♦

Hematocrit (35–45%)

38.53 ± 5.58 (27.50–48.10)

37.04 ± 6.05 (27.50–48.10)

40.65 ± 4.16 (32–46.60)

0.06●

Platelet (150–450 × 1000/µL)

268.76 ± 110.01 (95–609)

289.85 ± 122.86 (95–609)

238.64 ± 83.68 (101–374)

0.19●

Serum total protein (6.6–8.8 g/dL)

6.35 ± 0.78 (5.10–8.20)

6.54 ± 0.80 (5.10–8.20)

5.92 ± 0.58 (5.10–7.00)

0.08●

Albumin (3.5–5.3 g/dL)

4.00 ± 0.64 (3.10–5.10)

4.16 ± 0.63 (3.20–5.10)

3.71 ± 0.60 (3.10–4.60)

0.15●

Aspartate transaminase (up to 37 U/L)

26.48 ± 14.96 (10–64)

28 ± 15.53 (10–64)

24.38 ± 14.47 (11–62)

0.44●

Alanine transaminase (up to 41 U/L)

49.96 ± 75.35 (5–298)

46.11 ± 61.91 (12–242)

55.30 ± 93.34 (5–298)

0.31●

Alkaline phosphatase (80–306 U/L)

157.54 ± 37.53 (95–233)

143.38 ± 32.08 (95–187)

178 ± 36.83 (113–233)

0.03*●

Total bilirubin (0.1–1.2 mg/dL)

1.2 ± 0.52 (0.50–2.70)

1.17 ± 0.61 (0.50–2.70)

1.23 ± 0.37 (0.60–1.90)

0.29●

Lactate dehydrogenase (up to 513 U/L)

457.32 ± 135.85 (279–752)

445.45 ± 131.81 (298–740)

474.28 ± 144.66 (279–752)

0.55●

Creatine phosphokinase (24–195 U/L)

170.18 ± 64.69 (53–305)

190.15 ± 59.74 (56–305)

139.46 ± 61.84 (53–295)

0.03*●

Time between onset of poisoning and admission to hospital, SD = Standard deviation
* The difference between the two groups is significant at P < 0.05
** The difference between the two groups is significant at P < 0.005
▲
Chi-square test was used for statistical analysis
♦
Mann–Whitney U-test was used for statistical analysis
●
t-test was used for statistical analysis
$
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laboratory results. SAPSII was determined in the treatment
(4.7 ± 2) and control groups (5.05 ± 3.13). The results
showed no significant difference (P = 0.68).
Systolic blood pressure (SBP) significantly increased
during the first 24 h in the treatment group (89.16 ± 17.95
mmHg at admission vs. 98.95 ± 15.45 mmHg 24 h after
onset of poisoning, P < 0.05). The results also showed that
there was no significant difference between the two groups
due to SBP 24 h after the onset of poisoning (98.95 ± 15.45
mmHg in the treatment group vs. 89.21 ± 20.25 mmHg in
the control group, P = 0.13).
We observed significant increases in diastolic blood
pressure (DBP) in the treatment group (55.76 ± 11.03
mmHg at admission vs. 60.63 ± 13.58 mmHg 24 h after the
onset of poisoning, P < 0.05) and significant decreases in
DBP in the control group (60.67 ± 10.91 mmHg at admission
vs. 50.43 ± 12 mmHg 24 h after the onset of poisoning,
P < 0.05). The data showed a significant difference between
the two groups with regard to DBP 24 h after the onset of
poisoning (P < 0.05).
The results showed a significant difference in blood
pH between the treatment and control groups (7.43 ± 0.04
vs. 7.33 ± 0.1, P < 0.001) 24 h after onset of poisoning.
In addition, there was no significant difference between
the two groups due to PCO2 (36.24 ± 7.57 mmHg in the
treatment group vs. 34.19 ± 6.91 mmHg in the control
group, P = 0.4). We observed a significant difference in
serum bicarbonate between the two groups 24 h after the
onset of poisoning (24.22 ± 6.55 mEq/L in the treatment
group vs. 18.91 ± 5.62 mEq/L in the control group, P <
0.05).
There was no significant difference in the TAC of
plasma in the treatment and control groups at admission
(Table 2). Twenty-four hours after the onset of poisoning,
the TAC of plasma in the control group was significantly
higher than that in the treatment group (Table 2).

At admission, the plasma MDA level was not significantly
different between the treatment and control groups. The
plasma MDA level significantly decreased in the treatment
group and it significantly increased in the control group. The
plasma MDA level in the treatment group was significantly
lower than that in the control group 24 h after the onset of
poisoning (Table 2).
The percentage of patients who required intubation
and mechanical ventilation was significantly lower in the
treatment group than in the control group (30% vs. 62%, P <
0.05). In addition, the duration of intubation and mechanical
ventilation in the treatment group was significantly
lower compared to the control group. The total dose of
norepinephrine was not significantly different between the
two groups (Table 3).
Although the duration of hospitalization was not
significantly different between the two groups (Table 3), the
results showed that most of the fatality occurred during the
first 12 h after admission in the control group, and in the
treatment group most of the fatality was observed 20 h after
admission (Figure). In addition, the data showed that the
mortality rate was significantly lower in the treatment group
than in the control group (15% vs. 50%, P = 0.02).
4. Discussion
AlP poisoning is a major health problem with a high mortality
rate in Iran and other countries (2–4,6). Unfortunately, to
date, there is not a specific antidote for treatment of this type
of fatal poisoning and the only therapeutic measures are
supportive and symptomatic (9). In this regard, performing
studies that evaluate other therapeutic protocols is necessary.
There are many suggested mechanisms for AlP poisoning.
One of the most important mechanisms is involvement
of oxidative stress (10–14). From this viewpoint, the
antioxidants may have a therapeutic role in the treatment of
AlP poisoning (10,12).

Table 2. Comparison of plasma TAC and MDA levels at admission and 24 h after the onset of
poisoning in the treatment and control groups.
Parameters
MDA (µmol/L)
TAC (mmol/L)

Group

At admission
Mean ± SD

24 h after onset of
poisoning Mean ± SD

Treatment

130.91 ± 14.11■

124.88 ± 8.23▲

0.02*

Control

142.45 ± 29.28

151.51 ± 37.34

0.04*

Treatment

11.57 ± 6.05■

10.45 ± 3.48▲

0.23

Control

12.79 ± 3.63

13.26 ± 4.02

0.57

P-value

* The difference between two groups is significant at P < 0.05
There is no significant difference between the treatment and control groups at admission
▲
There is a significant difference between the treatment and control groups 24 h after the onset of
poisoning at P < 0.05
Mann–Whitney U-test was used for all the statistical analysis
■
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Table 3. Comparison of treatment and control groups according to duration of intubation, ventilation, hospitalization,
and dose of vasopressor
Parameters

Treatment group (n = 20)
Mean ± SD (range)

Control group (n = 16)
Mean ± SD (range)

P-value

Duration of intubation and ventilation (h)

4.15 ± 9 (0–32)

18.36 ± 28.37 (0–85.5)

0.04*

Total dose of norepinephrine (mg)

10.34 ± 14.35 (0–50.40)

10.15 ± 12.79 (0–43.20)

0.42

Duration of hospitalization (h)

69.09 ± 35.19 (21–159)

62.53 ± 68.87 (3.25–229)

0.16

*The difference between the two groups is significant at P < 0.05
t-test was used for all the statistical analysis

4
Control group
Treatment group

Number of fatal cases

3

2

1

0
2-6

6-12

12-18

18-24

24-30

30-36

Duration of hospitalization in nonsurvivors
(h)

Figure. Comparison of the duration of hospitalization between
nonsurvivors in the treatment and control groups.

Previous studies showed that vitamin E had a protective
role in the in vivo or in vitro toxicity of some poisons
through its antioxidant activity and lowering cell death
by decreased the levels of MDA, reactive oxygen species
production, and lipid peroxidation (18,23–25).
In the present study, we aimed to evaluate the efficacy
of intramuscular administration of vitamin E as an
antioxidant agent in patients with acute AlP poisoning.
The results showed significant rises in SBP and DBP
in the treatment group 24 h after the onset of poisoning,
which could be due to the role of vitamin E in reduction of
myocardial and vessels injury through the decrease in lipid
peroxidation (26,27).

The results in the control group showed progressive
metabolic acidosis during the first 24 h after the onset of
poisoning, which could be due to tissue hypoperfusion.
In the present study, the TAC and MDA levels at
admission showed no significant difference between the
two groups. In addition, the results showed that the serum
levels of MDA were significantly decreased after 24 h in
the treatment group, while in the control group they were
significantly increased. These results are in concordance of
our previous study, in which the administration of N-acetyl
cysteine as an antioxidant resulted in similar findings (12).
Vitamin E administration decreased the necessity for
intubation and mechanical ventilation and was associated
with a decrease in duration of intubation and mechanical
ventilation. This result was similar to that of our previous
study (12). Although in the previous studies mortality
rates of 60%–80% were reported in the AlP poisoning
cases with conventional supportive and symptomatic
treatment (7,28,29), in the present study administration of
vitamin E significantly reduced the mortality rate in the
treatment group compared to the control group (15% vs.
50%, respectively).
In conclusion, the present study showed that the
administration of vitamin E along with supportive
treatment decreased the mortality rate and so it could
be considered in the treatment of acute AlP poisoning in
combination with other therapeutic protocols.
The limitations of this study were small sample size and
lack of blinding in the study design.
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